Phase i study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 959-966

  Stuurman, F E ^a   Voest, E E ^b   Awada, A ^d   Witteveen, P O ^b   Bergeland, T ^e   Hals, P A ^e   Rasch, W ^e   Schellens, J H M ^a,c   Hendlisz, A ^d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d JULES BORDET INSTITUTE   (Belgium)

^e Clavis Pharma ASA   (Norway)

Author keywords

Cancer; Capsules; CO 1.01; CP 4126; dFdC; dFdU; Gemcitabine; Lipid; Oral; Oral administration; Phase 1; Phospholipids

Indexed keywords

2',2 DIFLUORODEOXYURIDINE; DRUG METABOLITE; GEMCITABINE; GEMCITABINE ELAIDATE; PRODRUG; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VOLUME; VAGINA CARCINOMA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; DEMOGRAPHY; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS;

EID: 84880921868     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9925-z     Document Type: Article

References (28)

1. Noble S, Goa KL (1997) Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54(3):447-472
2. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58(19):4349-4357
3. Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5(1):19-33
4. Burke T, Lee S, Ferguson PJ, Hammond JR (1998) Interaction of 2′,2′-difluorodeoxycytidine (gemcitabine) and formycin B with the Na + -dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells. J Pharmacol Exp Ther 286(3):1333-1340
5. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):7-12
6. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38(4):567-572
7. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51(22):6110-6117
8. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1992) Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52(3):533-539
9. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW (2006) Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20(6):849-855
10. Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23(5 Suppl 10):3-15
11. Banna GL, Collovà E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferraù F (2010) Anticancer oral therapy: emerging related issues. Cancer Treat Rev 36(8):595-605
12. Kerbel RS, Kamen B (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423-436
13. André N, Padovani L, Pasquier E (2011) Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol 7(3):385-394
14. Cham KKY, Baker JHE, Takhar KS et al (2010) Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer 103(1):52-60
15. Laquente B, Lacasa C, Ginestà MM, Casanovas O, Figueras A, Galán M, Ribas IG, Germà JR, Capellà G, Viñals F (2008) Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 7(3):638-647
16. Veltkamp SA, Jansen RS, Callies S et al (2008) Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 14(11):3477-3486
17. Bender DM, Bao J, Dantzig AH et al (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 52(22):6958-6961
18. Koolen SLW, Witteveen PO, Jansen RS et al (2011) Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res 17(18):6071-6082
19. Adema AD, Bijnsdorp IV, Sandvold ML, Verheul HM, Peters GJ (2009) Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer. Curr Med Chem 16(35):4632-4643
20. Bergman AM, Adema AD, Balzarini J et al (2011) Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs 29(3):456-466
21. Adema AD, Smid K, Losekoot N, Honeywell RJ, Verheul HM, Myhren F, Sandvold ML, Peters GJ (2012) Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest New Drugs 30(5):1908-1916
22. Eisenhauer E, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
23. Lilly E Gemzar 200 mg powder for solution for infusion, Gemzar 1000 mg powder for solution for infusion. Summary of Product Characteristics (SPC)
24. Fukami T, Yokoi T (2012) The emerging role of human esterases. Drug Metab Pharmacokinet 27(5):466-477
25. Abbruzzese JL, Grunewald R, Weeks EA, D G, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9(3):491-498
26. Peters GJ, Clavel M, Noordhuis P, Geyssen GJ, Laan AC, Guastalla J, Edzes HT, Vermorken JB (2007) Clinical phase I and pharmacology study of gemcitabine (2′, 2′-difluorodeoxycytidine) administered in a two-weekly schedule. J Chemother 19(2):212-221
27. Stuurman FE, Lolkema MPJ, Soetekouw PMMB, Rosing H, Mergui-Roelvink M, Beijnen JH, Voest EE, Van Tinteren H, Huitema ADR, Schellens JHM (2012) 581 an adaptive, 2-stage, phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors. Eur J Cancer Supp 48(supp 6):178
28. Veltkamp S, Pluim D, Van Eijndhoven MAJ, Bolijn MJ, Ong FHG, Govindarajan R, Unadkat JD, Beijnen JH, Schellens JHM (2008) New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′- difluorodeoxyuridine. Mol Cancer Ther 7(8):2415-2425